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11 73-12 DO Multiple Prior Interventions for  In-Stent Rsetenosls 
Impact the Success of Gamma Brachytherapy? 
Stratum 
Dale T. Ashby. G. Dangas, R. Mehran, A. J. Lansky, M. Adamien, M. Collins, E, Krepps, I 
G. New, L Mousse, G. W, Stone, G. S. Roubin, S. lyer, J. W. Moses, M. B. Leon, P. S. 
Teirstein, Lenox Hill Heart and Vascular Institute, New York, New York, SCRIPPS Clinic, 
La Jolla, California. 
Background: Multiple prior episodes of in-stent restenosis (ISR) is a risk factor for sub- 
sequent recurrrance after PTCA or stenting. However, whether the number of prior target 
lesion ISR adversely affects the clinical success of brachytherapy for ISR is unknown. 
Method: SCRIPPS III is a 500 patient multicentar egistry utilizing localized Ir-192 
gamma brachytherapy for ISR. Pts fn SCRIPPS III were divided into 3 groups according II 
to the number of prior interventions to the target lesion: 1 prior PCI (n=211); 2 prior PCIs 
(n=170); and >3 prior PCIs (n=86). Procedural and 6 month clinical outcomes were 
examined. 
Results: There were no significant differences in baseline patient and lesion characteris- 
tics, procedural outcomes and in-hospital results between the 3 groups. There was no 
significant difference in the average seed length between the groups. There were no epi- 
sodes of late stent thrombosis beyond 30 days. 
1 prior PCl 2 prior PCle ->3 prior PCls P 
(n=211) (n=170) (n--86) 
Diabetes (%) 37.4 31.8 34.9 0.51 
Target Lesion Length (mm) 29 ± 19 28 ± 17 31 ± 21 0.43 
30-day Stent Thrombosis 0.0 0,6 2.4 0.04 
Clinical Events at 9 Months 
JACC March 6, 2002 
SES US p-value 
Parameter 
n 37 38 ns 
RD (mm) 2.05±0.20 2.08±0.21 ns 
MLD post (mm) 2.03±0.25 2.07±0.29 ns 
MLD fup (mm) 2.05±0.32 1.22¢0.46 <0.001 
LL (mm) -0.01¢0.25 0.85±0.52 <0.001 
Restenosis rate (%) 0 37.1 <0.001 
n 40 38 ns 
RD (ram) 2.53±0.14 2.61±0.14 ns 
MLD post (mm) 2.38±0.28 2.39±0.26 ns 
MLD fup (mm) 2.35¢0.39 1.68±0.45 <0.001 
LL (mm) 0.03±0.34 0.79±0.51 <0.001 
Restenosis rate (%) 0 20.6 <0.001 
n 39 38 ns 
RD (mm) 3.21±0.39 3.22±0.29 ns 
MLD post (mm) 2.80±0.28 2.72±0.29 ns 
MLD fup (mm) 2.83±0.36 1.97±0.55 <0.001 
LL (mm) -0.04±0.25 0.76±0.58 <0.001 
Rastenosis rate (%) 0 20.0 <0.001 
MACE* (%) 21.3 15.5 27.7 0.07 
Death (%) 4.0 2.5 1.2 0.50 
MI (%) 6.5 3.7 3.7 0.44 
TLR (%) 15.3 13.0 25.3 0.04 
TVR (%) 20.3 19.3 28.9 0.19 
*MACE= Death, MI, or target lesion revascularization (TLR) 
Conclusions: Patients with history of multiple episodes of prior in-stent restenosis are at 
higher dsk for target lesion revascularization and sub-acute thrombosis even after 
gamma vascular brachytherapy. These high-risk patients may require special consider- 
ations such as brechytherapy dose adjustments or other therapies such as drug-eluting 
stents. 
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1174-13 SlrolImus Inhibits Restenoaia Irrespective of the Vessel 
Slze: A Subanalysls of the Multlcenter RAVEL Trial 
Evelyn Reoar, G. Laarman, D. Blanchard, H. Eitchaninoff, J. E. Souse, J. Fajedet, M 
Perin, E. Ban Hayashi, M. C. Modce, P. W. Serruys, Thoraxcenter, Rotterdam, The 
Netherlands. 
Introduction: Vessel size is an established predictor of angiographic outcome after cath- 
eter-based intervention. Neointimal growth is a uniform vascular reaction to vessel injury. 
Small vessels tend to have relatively more neointimal hyperplasia than larger vessels. 
Aim: To investigate the relationship between vessel size and late lumen loss after 
implantation of Sirolimus-eluting stents. 
Methods: We analyzed the angiographic outcome of patients, who were prospectively 
included in the multi center RAVEL trial Patients with de-novo lesions were randomized 
to receive an 18mm Sirolimus-eluting Bx VELOCITY trn stent (SES) (Cordis) or a 
uncoated t8mm Bx VELOCITY tm (US) stent. Quantitative coronary analysis was per* 
formed at baseline and at 6-month follow-up (fup). Vessels were stratified in tsmiles 
according to their diameter (RD). Late lumen loss (LL) was calculated as "MLD post pro- 
cedure (post) - MLD fup'. 
Results: 
Conclusion: The classical negative relation between vessel size and late lumen loss 
was seen in the US group, but not in the SES group. SES prevents neointimal growth 
and late lumen loss irrespective of the vessel size. 
1174-14 The Absence of Edge Effect After Implantation of 
Sirol lmus-Elut lng Stents to Treat In-Stent Reatenoals: A 
Three-Dimensional Intravascular Ultrasound Volumetric 
Analysis 
Alexandre Abtzaid. Patrick Serruys, Andrea Abizaid, Fausto Feres, Marinella Centemaro, 
Luiz A. Mattos, Judith L. Jaeger, David Foley, Yoshio Kobayashi, Pim de Feytar, Amanda 
Souse, J. Eduardo Souse, institute Dante Pazzanase of Cardiology, Sao Pau/o, Brazil 
Background: "Edge effect' has become an important issue in assessing new technolo- 
gies for inhibiting restenosis (i.e. brachytherapy). We sought to determine whether there 
is an 'edge effect' after implantating Sirolimus-eluting (SE) BX velocity stents to treatin- 
stent restenosis (ISR). Methods: Forty patients with ISR in native coronary artedas were 
treated with one or two 18mm SE stents (mean stent length 23.3±7.1 mm). Serial volu- 
metric intravascular ultrasound (IVUS) measurements were obtained at baseline and 4 
months, including the t 0mm long reference segments adjacent o the proximal and distal 
edges of the stent. Volumes were normalized for the lengths of the reference segments, 
and mean areas are reported (Table). Result=: In the 22 pts that underwent 4-month 
angiographic and IVUS folicw-up, there was no recurrence either within the stent or at 
the stant edges. At follow-up, IVUS in-stent intimal hyperplasia volume measured 
6.3±5.6mm 3,occupying only 5% of the stent volume. Serial IVUS analysis showed nei- 
ther positive nor negative arterial remodeling, no increase in proximal or distal edge 
plaque, and no changes in edge lumen dimensions. 
Post Follow-up A p 
Proximal edge 
Arterial area, m m 2 13.4±3.7 13.2±4.2 0.18 N S 
Lumen area, mm 2 7.6±3.5 7.6+4.0 0.01 NS 
Plaque area, mm 2 6.3±2.2 6.2±.2.6 0.10 NS 
Distal edge 
Arterial area, mm 2 10,1±4.2 10.1±3.1 -0.03 NS 
Lumen area, mm 2 5.7±2.3 5.6±2.2 0.05 NS 
Plaque area, mm 2 4.3.±.2,6 4.3±2,2 0.01 NS 
Conclusion: This preliminary registry using the Sirolimus-eluting stant to treat in-stent 
restenosis demonstrates the beneficial antiproliferative effects of Sirolimus in eliminating 
in-stent neointima formation while preserving peri-stent vessel dimensions without detri- 
mental 'edge effects'. 
1174-15 Safety and Performance of s PacUtaxeI-Elutlng Stent for 
the Treatment of In-Stent Rsetenosis: Pral lmlnary 
Results of the Taxus III Trial 
Eberhard Grube, Parick W. Serruys, Herzzentrum Siegburg, Siegburg, Germany, Heart 
Center, Academic Hospital, Rotterdam-Dijkzigt, The Netherlands. 
Background: The success of coronary stenting for atherosclerotic oronary artery dis- 
ease has been limited by in-stent restenosis (ISR). The use of polymer-controlled deliv- 
ery of the anti-metabolic agent Paclitaxel has been under investigation for the treatment 
of de novo coronary lesions. Taxus III was designed as a two-oanter egistry to determine 
the feasibility of using this technology for the treatment of ISR. 
Methods: Patients with stable angina, unstable angina with documented ischemia, or 
silent ischemia with angiographically defined ISR, were enrolled. Acceptable lesions for 
